MedTrace Logo

Levetiracetam in the Management of Bipolar Depression

NCT00566150 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.

Conditions

Interventions

DRUG

Levetiracetam

Flexible dose up to 2500mg per day, for 6 weeks.

DRUG

Placebo

Flexible dose up to 2500mg per day, for 6 weeks.

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Zubin Bhagwagar, MD PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566150 on ClinicalTrials.gov